Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

45

Enrollment

NIH

Sponsor class

Conditions

Influenza Prevention
Seasonal Influenza

Interventions

BIOLOGICAL: VRC-FLUMOS0116-00-VP
OTHER: ALFQ

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)